JP2016526016A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016526016A5 JP2016526016A5 JP2016512011A JP2016512011A JP2016526016A5 JP 2016526016 A5 JP2016526016 A5 JP 2016526016A5 JP 2016512011 A JP2016512011 A JP 2016512011A JP 2016512011 A JP2016512011 A JP 2016512011A JP 2016526016 A5 JP2016526016 A5 JP 2016526016A5
- Authority
- JP
- Japan
- Prior art keywords
- fgfr1
- medicament according
- medicament
- ecd
- fusion molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 33
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 claims 13
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 claims 13
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 claims 13
- 230000004927 fusion Effects 0.000 claims 13
- 206010028980 Neoplasm Diseases 0.000 claims 12
- 201000011510 cancer Diseases 0.000 claims 12
- 101150016624 fgfr1 gene Proteins 0.000 claims 11
- 210000004027 cell Anatomy 0.000 claims 10
- 230000002018 overexpression Effects 0.000 claims 8
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 7
- 229930012538 Paclitaxel Natural products 0.000 claims 7
- 190000008236 carboplatin Chemical compound 0.000 claims 7
- 229960004562 carboplatin Drugs 0.000 claims 7
- 229960003668 docetaxel Drugs 0.000 claims 7
- 229960001592 paclitaxel Drugs 0.000 claims 7
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 7
- 230000004544 DNA amplification Effects 0.000 claims 6
- 210000002230 centromere Anatomy 0.000 claims 3
- 210000000349 chromosome Anatomy 0.000 claims 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 3
- 102100037985 Dickkopf-related protein 3 Human genes 0.000 claims 2
- 102100039578 ETS translocation variant 4 Human genes 0.000 claims 2
- 102100035323 Fibroblast growth factor 18 Human genes 0.000 claims 2
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 claims 2
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 claims 2
- 101000951342 Homo sapiens Dickkopf-related protein 3 Proteins 0.000 claims 2
- 101000813747 Homo sapiens ETS translocation variant 4 Proteins 0.000 claims 2
- 101000878128 Homo sapiens Fibroblast growth factor 18 Proteins 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 238000000018 DNA microarray Methods 0.000 claims 1
- 102100035290 Fibroblast growth factor 13 Human genes 0.000 claims 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims 1
- 238000002105 Southern blotting Methods 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- -1 at least 5 mg / kg Chemical compound 0.000 claims 1
- 230000000052 comparative effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000002509 fluorescent in situ hybridization Methods 0.000 claims 1
- 238000009396 hybridization Methods 0.000 claims 1
- 238000003364 immunohistochemistry Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 238000003753 real-time PCR Methods 0.000 claims 1
- 238000003757 reverse transcription PCR Methods 0.000 claims 1
- 238000012163 sequencing technique Methods 0.000 claims 1
- 230000003595 spectral effect Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361818220P | 2013-05-01 | 2013-05-01 | |
| US61/818,220 | 2013-05-01 | ||
| US201361831029P | 2013-06-04 | 2013-06-04 | |
| US61/831,029 | 2013-06-04 | ||
| PCT/US2014/036140 WO2014179448A2 (en) | 2013-05-01 | 2014-04-30 | Methods of treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016526016A JP2016526016A (ja) | 2016-09-01 |
| JP2016526016A5 true JP2016526016A5 (enExample) | 2017-06-15 |
Family
ID=50928263
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016512011A Pending JP2016526016A (ja) | 2013-05-01 | 2014-04-30 | がんを治療する方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20160067307A1 (enExample) |
| EP (1) | EP2991669A2 (enExample) |
| JP (1) | JP2016526016A (enExample) |
| KR (1) | KR20160003141A (enExample) |
| CN (1) | CN105188732A (enExample) |
| AU (1) | AU2014259956A1 (enExample) |
| BR (1) | BR112015027607A8 (enExample) |
| CA (1) | CA2908391A1 (enExample) |
| HK (1) | HK1213817A1 (enExample) |
| MX (1) | MX2015015115A (enExample) |
| RU (1) | RU2015150233A (enExample) |
| SG (1) | SG11201508878WA (enExample) |
| WO (1) | WO2014179448A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1910542B1 (en) | 2005-07-22 | 2009-12-02 | Five Prime Therapeutics, Inc. | Compositions and methods of treating disease with fgfr fusion proteins |
| US8481038B2 (en) | 2010-11-15 | 2013-07-09 | Five Prime Therapeutics, Inc. | Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins |
| CA2855818A1 (en) | 2011-11-14 | 2013-05-23 | Five Prime Therapeutics, Inc. | A method of treating lung cancer having an fgfr1 gene amplification or fgfr1 overexpression |
| RU2698061C2 (ru) | 2013-08-01 | 2019-08-21 | Файв Прайм Терапьютикс, Инк. | АФУКОЗИЛИРОВАННЫЕ АНТИТЕЛА К РЕЦЕПТОРУ ФАКТОРА РОСТА ФИБРОБЛАСТОВ FGFR2IIIb |
| CN108026588A (zh) * | 2015-07-24 | 2018-05-11 | 德彪药业国际股份公司 | Fgfr表达以及对fgfr抑制剂的敏感性 |
| CN116327924A (zh) * | 2015-11-23 | 2023-06-27 | 戊瑞治疗有限公司 | 用于癌症治疗的单独fgfr2抑制剂或与免疫刺激剂的组合 |
| PL238516B1 (pl) | 2016-06-13 | 2021-08-30 | Univ Wroclawski | Sposób otrzymywania modyfikowanego polipeptydu |
| CA3048916A1 (en) * | 2017-02-06 | 2018-08-09 | Rainier Therapeutics, Inc. | Methods, compositions, and kits for treatment of cancer |
| WO2018195273A1 (en) * | 2017-04-19 | 2018-10-25 | The Corporation Of Mercer University | Sam-1 protein, composition and methods of use |
| CA3062177A1 (en) | 2017-05-16 | 2018-11-22 | Five Prime Therapeutics, Inc. | Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment |
| EP3915576A1 (en) * | 2020-05-28 | 2021-12-01 | Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron | Chimeric antigen receptors specific for p95her2 and uses thereof |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
| EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| US5700637A (en) | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
| JP2989002B2 (ja) | 1988-12-22 | 1999-12-13 | キリン―アムジエン・インコーポレーテツド | 化学修飾顆粒球コロニー刺激因子 |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| ATE240740T1 (de) | 1991-03-15 | 2003-06-15 | Amgen Inc | Pegylation von polypeptiden |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
| ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
| US6573043B1 (en) | 1998-10-07 | 2003-06-03 | Genentech, Inc. | Tissue analysis and kits therefor |
| CA2348292A1 (en) | 1998-10-30 | 2000-05-11 | Takeda Chemical Industries, Ltd. | Betacellulin protein-containing preparation |
| AU2001249727A1 (en) | 2000-03-31 | 2001-10-15 | Genentech, Inc. | Compositions and methods for detecting and quantifying gene expression |
| CN109395082A (zh) | 2000-05-19 | 2019-03-01 | 杰南技术公司 | 用于提高对ErbB拮抗剂癌症治疗的有效应答可能性的基因检测试验 |
| US20050209310A1 (en) * | 2000-12-22 | 2005-09-22 | Chaplin David J | Methods for modulating tumor growth and metastasis |
| US6900292B2 (en) | 2001-08-17 | 2005-05-31 | Lee-Hwei K. Sun | Fc fusion proteins of human erythropoietin with increased biological activities |
| PL1638941T3 (pl) | 2003-05-22 | 2010-11-30 | Abbvie Bahamas Ltd | Indazolowe, benzizoksazolowe i benzizotiazolowe inhibitory kinaz |
| WO2006076288A2 (en) | 2005-01-11 | 2006-07-20 | Five Prime Therapeutics, Inc. | Dna constructs for long-term expression of intravascularly injected naked dna |
| EP1910542B1 (en) | 2005-07-22 | 2009-12-02 | Five Prime Therapeutics, Inc. | Compositions and methods of treating disease with fgfr fusion proteins |
| JP2009514879A (ja) * | 2005-11-04 | 2009-04-09 | メルク エンド カムパニー インコーポレーテッド | Ｓａｈａ、カルボプラチン及びパクリタキセルを用いて癌を治療する方法及びその他の併用療法 |
| ES2342646B1 (es) | 2008-06-02 | 2011-04-26 | Institut De Recerca Hospital Universitari Vall Hebron | Metodo de diagnostico de canceres que expresan el receptor her-2 o sus variantes truncadas. |
| US8481038B2 (en) * | 2010-11-15 | 2013-07-09 | Five Prime Therapeutics, Inc. | Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins |
| WO2012068032A1 (en) * | 2010-11-15 | 2012-05-24 | Five Prime Therapeutics, Inc. | Fgfr1 extracellular domain combination therapies |
| US8951972B2 (en) * | 2010-12-09 | 2015-02-10 | Five Prime Therapeutics, Inc. | FGFR1 extracellular domain combination therapies for lung cancer |
| CA2855818A1 (en) * | 2011-11-14 | 2013-05-23 | Five Prime Therapeutics, Inc. | A method of treating lung cancer having an fgfr1 gene amplification or fgfr1 overexpression |
-
2014
- 2014-04-30 MX MX2015015115A patent/MX2015015115A/es unknown
- 2014-04-30 EP EP14729530.7A patent/EP2991669A2/en not_active Withdrawn
- 2014-04-30 KR KR1020157033756A patent/KR20160003141A/ko not_active Withdrawn
- 2014-04-30 CN CN201480024106.3A patent/CN105188732A/zh active Pending
- 2014-04-30 CA CA2908391A patent/CA2908391A1/en not_active Abandoned
- 2014-04-30 AU AU2014259956A patent/AU2014259956A1/en not_active Abandoned
- 2014-04-30 US US14/785,691 patent/US20160067307A1/en not_active Abandoned
- 2014-04-30 WO PCT/US2014/036140 patent/WO2014179448A2/en not_active Ceased
- 2014-04-30 RU RU2015150233A patent/RU2015150233A/ru not_active Application Discontinuation
- 2014-04-30 JP JP2016512011A patent/JP2016526016A/ja active Pending
- 2014-04-30 BR BR112015027607A patent/BR112015027607A8/pt not_active IP Right Cessation
- 2014-04-30 SG SG11201508878WA patent/SG11201508878WA/en unknown
- 2014-04-30 HK HK16101949.2A patent/HK1213817A1/zh unknown
-
2018
- 2018-01-03 US US15/861,047 patent/US20180280470A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016526016A5 (enExample) | ||
| Wang et al. | Somatic gene copy number alterations in colorectal cancer: new quest for cancer drivers and biomarkers | |
| Wood et al. | Molecular histology of lung cancer: from targets to treatments | |
| Lee et al. | Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers | |
| Memon et al. | The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients | |
| Buss et al. | The WIP1 oncogene promotes progression and invasion of aggressive medulloblastoma variants | |
| Custodio et al. | Pharmacogenetic predictors of severe peripheral neuropathy in colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy: a GEMCAD group study | |
| JP2015505818A5 (enExample) | ||
| JP2016169229A5 (enExample) | ||
| Sato et al. | Genome-wide association study on overall survival of advanced non-small cell lung cancer patients treated with carboplatin and paclitaxel | |
| IL259672B2 (en) | Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-vegf | |
| Gorbatenko et al. | ErbB2 upregulates the Na+, HCO3‐‐cotransporter NBCn1/SLC4A7 in human breast cancer cells via Akt, ERK, Src, and Krüppel‐like factor 4 | |
| Bian et al. | RPL13A as a reference gene for normalizing mRNA transcription of ovarian cancer cells with paclitaxel and 10-hydroxycamptothecin treatments | |
| RU2015150233A (ru) | Способы лечения злокачественной опухоли | |
| Zhou et al. | Gene microarray analysis of lncRNA and mRNA expression profiles in patients with hypopharyngeal squamous cell carcinoma | |
| Lee et al. | ERBB2 kinase domain mutation in the lung squamous cell carcinoma | |
| Aklillu et al. | Frequency of the SLCO1B1 388A> G and the 521T> C polymorphism in Tanzania genotyped by a new LightCycler®-based method | |
| Galeș et al. | Next-Generation Sequencing in Oncology—A Guiding Compass for Targeted Therapy and Emerging Applications | |
| Tian et al. | Microarray expression profile of long non-coding RNAs in paclitaxel-resistant human lung adenocarcinoma cells | |
| Jiang et al. | The impact of functional LIG4 polymorphism on platinum-based chemotherapy response and survival in non-small cell lung cancer | |
| Walter et al. | microRNAs are differentially regulated between MDM2-positive and negative malignant pleural mesothelioma | |
| Tan et al. | Single nucleotide polymorphism rs13042395 in the SLC52A3 gene as a biomarker for regional lymph node metastasis and relapse-free survival of esophageal squamous cell carcinoma patients | |
| CN106399582B (zh) | 一种检测与结直肠癌靶向用药西妥昔单抗治疗敏感性相关基因的多态性的试剂盒及其应用 | |
| Zheng et al. | Genetic variability of ERCC1 and ERCC2 genes involved in the nucleotide excision repair pathway influences the treatment outcome of gastric cancer | |
| Soundararajan et al. | Function of tumor suppressors in resistance to antiandrogen therapy and luminal epithelial plasticity of aggressive variant neuroendocrine prostate cancers |